IP Library › Granted Patent US 12,396,970
Granted Patent B2
US 12,396,970 · App. 17/892,301 · Granted Aug 26, 2025

Anti-arrhythmic compositions and methods

Inventors: Brandon Ira Kashfian (Chicago, IL); Jodi Devlin (Chicago, IL)
Assignee: AltaThera Pharmaceuticals LLC
A61K31/18A61P9/06A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,970
App. No.
17/892,301
Granted
Aug 26, 2025
Kind
B2
Abstract

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg/kg bodyweight over a duration of up to 60 minutes can be administered and/or a maintenance dose of 0.1 to 10 μg/kg/hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and/or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and/or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

Claims (81)

1. A method, comprising:

administering 1.5-5.5 μg/kg dofetilide to a patient by way of an intravenous (IV) loading dose over a duration of at least 1 hour and in an amount effective for treating or preventing a cardiovascular condition of the patient;

wherein the amount of dofetilide in the IV loading dose is in the range of about:

±50% of the amount of dofetilide in a target maintenance dose; and

the target maintenance dose is a 250 μg oral dose of dofetilide.

2. The method of claim 1 , wherein the cardiovascular condition is selected from atrial fibrillation, atrial flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, pulmonary artery hypertension, atrial tachycardia, junctional ectopic tachycardia, or junctional tachycardia.

3. The method of claim 1 , further comprising:

measuring a creatinine clearance of the patient before administering the IV loading dose of dofetilide; and

selecting or adjusting the effective amount of the IV loading dose based on the creatinine clearance of the patient.

4. The method of 3 , further comprising administering to the patient one or more:

oral dose of dofetilide; or

IV maintenance dose of dofetilide selected from an amount ranging from 0.1-10 μg/kg.

5. The method of claim 4 , wherein the patient is NPO and/or unable to take oral dofetilide and is administered the one or more IV maintenance dose of dofetilide.

6. The method of claim 1 , wherein the patient has a creatinine clearance in the range of 20-60 mL/min.

7. A method, comprising:

administering an intravenous (IV) loading dose of dofetilide:

to a patient who is currently in normal sinus rhythm;

in an amount effective for treating atrial fibrillation or atrial flutter;

in the range of >3 μg/kg and <12 μg/kg;

over a duration of at least 1 hour; and

administering at least one dose of oral dofetilide to the patient in an amount of 250 μg or 500 μg.

8. A method, comprising:

administering 0.8-3 μg/kg dofetilide to a patient by way of an intravenous (IV) loading dose over a duration of at least 1 hour and in an amount effective for treating or preventing a cardiovascular condition of the patient;

wherein the amount of dofetilide in the IV loading dose is in the range of about:

±50% of the amount of dofetilide in a target maintenance dose; or

the target maintenance dose is a 125 μg oral dose of dofetilide.

9. The method of claim 8 , wherein the cardiovascular condition is selected from atrial fibrillation, atrial flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, pulmonary artery hypertension, atrial tachycardia, junctional ectopic tachycardia, or junctional tachycardia.

10. The method of claim 8 , further comprising:

administering to the patient one or more:

oral dose of dofetilide; or

IV maintenance dose of dofetilide in the range of 0.1-10 μg/kg.

11. A method, comprising:

measuring a creatinine clearance of a patient;

selecting an amount of an intravenous (IV) loading dose of dofetilide based on the creatinine clearance of the patient, wherein the amount is effective for treating or preventing a cardiovascular condition of the patient;

administering the IV loading dose of dofetilide to the patient over a duration of at least 1 hour and in an amount that is:

between +5% to +50% of a target maintenance dose; or

between −5% to −50% of the target maintenance dose; and

administering to the patient one or more:

oral dose of dofetilide; or

IV maintenance dose of dofetilide in the range of 0.1-10 μg/kg.

12. The method of claim 11 , wherein the cardiovascular condition is selected from atrial fibrillation, atrial flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, pulmonary artery hypertension, atrial tachycardia, junctional ectopic tachycardia, or junctional tachycardia.

13. The method of claim 11 , wherein the patient is NPO and/or unable to take oral dofetilide and is administered the one or more IV maintenance dose of dofetilide.

14. The method of claim 11 , wherein the IV loading dose of dofetilide is in an amount of between +5% to +25% of the target maintenance dose.

15. The method of claim 14 , further comprising administering the one or more oral dose of dofetilide.

16. The method of claim 11 , wherein:

the amount of the IV loading dose is in the range of 1.7-5.5 μg/kg; and

the patient has a creatinine clearance in the range of 40 to 60 mL/min.

17. The method of claim 11 , wherein:

the amount of the IV loading dose is in the range of 0.8-2.8 μg/kg; and

the patient has a creatinine clearance in the range of 20 to <40 mL/min.

18. The method of claim 11 , wherein:

the amount of the IV loading dose is in the range of 3.5-11 μg/kg; and

the patient has a creatinine clearance of >60 mL/min.

19. The method of claim 18 , comprising:

performing ECG monitoring of the patient;

at 2-3 hours after administering the IV loading dose of dofetilide, obtaining a QTc of the patient and determining the QTc of the patient has not increased by greater than 15% from a baseline QTc of the patient or is not greater than 500 msec (550 msec in patients with ventricular conduction abnormalities); and

administering the one or more oral dose of dofetilide to the patient, optionally twice daily, in an amount of:

i. 500 mcg, when the creatinine clearance of the patient is >60 mL/min;

ii. 250 mcg, when the creatinine clearance of the patient is 40 to 60 mL/min; or

iii. 125 mcg, when the creatinine clearance of the patient is 20 to <40 mL/min.

20. The method of claim 18 , comprising:

performing ECG monitoring of the patient;

at 2-3 hours after administering the IV loading dose of dofetilide, obtaining a QTc of the patient, and determining the QTc of the patient has increased by greater than 15% from a baseline QTc of the patient or is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities); and

administering the one or more oral dose of dofetilide, in an amount of:

i. 250 mcg, twice daily, for a patient with a creatinine clearance of >60 mL/min;

ii. 125 mcg, twice daily, for a patient with a creatinine clearance of 40 mL/min to 60 mL/min; or

iii. 125 mcg, once daily, for a patient with a creatinine clearance of 20 mL/min to <40 mL/min.

21. The method of claim 18 , comprising:

performing ECG monitoring of the patient;

at 2-3 hours after administering the IV loading dose of dofetilide, obtaining a QTc of the patient and determining the QTc of the patient has not increased by greater than 15% from a baseline QTc of the patient or is not greater than 500 msec (550 msec in patients with ventricular conduction abnormalities); and

administering the one or more IV maintenance dose of dofetilide to the patient, optionally twice daily, in an amount of:

i. 3.5-11 μg/kg, when the creatinine clearance of the patient is >60 mL/min;

ii. 1.5-6 μg/kg, when the creatinine clearance of the patient is 40 to 60 mL/min; or

iii. 0.8-3 μg/kg, when the creatinine clearance of the patient is 20 to <40 mL/min.

22. The method of claim 18 , comprising:

performing ECG monitoring of the patient;

at 2-3 hours after administering the IV loading dose of dofetilide, obtaining a QTc of the patient, and determining the QTc of the patient has increased by greater than 15% from a baseline QTc of the patient or is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities); and

administering one or more IV maintenance dose of dofetilide, in an amount of:

i. 1.5-6 μg/kg, twice daily, for a patient with a creatinine clearance of >60 mL/min;

ii. 0.8-3 μg/kg, twice daily, for a patient with a creatinine clearance of 40 mL/min to 60 mL/min; or

iii. 0.4-3 μg/kg, once or twice daily, for a patient with a creatinine clearance of 20 mL/min to <40 mL/min.

Assignments (2)
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Jul 14, 2023
From: SAGARD HEALTHCARE ROYALTY PARTNERS, LP
To: SAGARD HEALTHCARE PARTNERS (DELAWARE) LP
Reel/Frame 064275/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2022
From: KASHFIAN, BRANDON IRA; DEVLIN, JODI
To: ALTATHERA PHARMACEUTICALS LLC
Reel/Frame 061867/0033 →
Continuity (9)
Continuation In Part 17566840 · Dec 31, 2021
Provisional Application 63345068 · May 24, 2022
Provisional Application 63344154 · May 20, 2022
Provisional Application 63340581 · May 11, 2022
Provisional Application 63334267 · Apr 25, 2022
Provisional Application 63331905 · Apr 18, 2022
Provisional Application 63276947 · Nov 8, 2021
Provisional Application 63235500 · Aug 20, 2021
Related Publication 20230172883A1 · Jun 8, 2023
References Cited (400)
US 6043273A · Duhaylongsod · 2000 [cited by applicant]
US 6060454A · Duhaylongsod · 2000 [cited by applicant]
US 6101412A · Duhaylongsod · 2000 [cited by applicant]
US 6124363A · Appleby et al. · 2000 [cited by applicant]
US 6136327A · Gupta et al. · 2000 [cited by applicant]
US 6281246B2 · Sankaranarayanan · 2001 [cited by applicant]
US 6369114B1 · Weil et al. · 2002 [cited by applicant]
US 6482811B1 · Bacaner et al. · 2002 [cited by applicant]
US 6491039B1 · Dobak, III · 2002 [cited by applicant]
US 6500459B1 · Chhabra et al. · 2002 [cited by applicant]
US 6544981B2 · Stein et al. · 2003 [cited by applicant]
US 6627223B2 · Percel et al. · 2003 [cited by applicant]
US 6632217B2 · Harper et al. · 2003 [cited by applicant]
US 6645524B2 · Midha et al. · 2003 [cited by applicant]
US 6720001B2 · Chen et al. · 2004 [cited by applicant]
US 6800668B1 · Odidi et al. · 2004 [cited by applicant]
US 6899700B2 · Gehling et al. · 2005 [cited by applicant]
US 6916813B2 · Atwal et al. · 2005 [cited by applicant]
US 6944638B1 · Putnam · 2005 [cited by applicant]
US 7004171B2 · Benita et al. · 2006 [cited by applicant]
US 7005425B2 · Belardinelli et al. · 2006 [cited by applicant]
US 7005436B2 · Lloyd et al. · 2006 [cited by applicant]
US 7022343B2 · Philbrook et al. · 2006 [cited by applicant]
US 7048945B2 · Percel et al. · 2006 [cited by applicant]
US 7090830B2 · Hale et al. · 2006 [cited by applicant]
US 7179597B2 · Woosley · 2007 [cited by applicant]
US 7289847B1 · Gill et al. · 2007 [cited by applicant]
US 7341737B2 · Gehling et al. · 2008 [cited by applicant]
US 7371254B2 · Dobak, III · 2008 [cited by applicant]
US 7396524B2 · Yan · 2008 [cited by applicant]
US 7417038B1 · Anker et al. · 2008 [cited by applicant]
US 7526335B2 · Ferek-Petric · 2009 [cited by applicant]
US 7538092B2 · Orlando et al. · 2009 [cited by applicant]
US 7572776B2 · Yu et al. · 2009 [cited by applicant]
US 7674820B2 · Fedida et al. · 2010 [cited by applicant]
US 7745665B2 · Gant et al. · 2010 [cited by applicant]
US 7765110B1 · Koneru · 2010 [cited by applicant]
US 7776844B2 · Yu et al. · 2010 [cited by applicant]
US 7815936B2 · Hasenzahl et al. · 2010 [cited by applicant]
US 7829573B2 · Curwen et al. · 2010 [cited by applicant]
US 7846968B2 · Chien et al. · 2010 [cited by applicant]
US 7885824B1 · Koneru · 2011 [cited by applicant]
US 7885827B1 · Koneru · 2011 [cited by applicant]
US 7951183B2 · Dobak, III · 2011 [cited by applicant]
US 8106099B2 · Brendel et al. · 2012 [cited by applicant]
US 8236782B2 · Mosher et al. · 2012 [cited by applicant]
US 8263125B2 · Vaya et al. · 2012 [cited by applicant]
US 8268352B2 · Vaya et al. · 2012 [cited by applicant]
US 8313757B2 · Lengerich · 2012 [cited by applicant]
US 8377994B2 · Gray et al. · 2013 [cited by applicant]
US 8399018B2 · Lichter et al. · 2013 [cited by applicant]
US 8440168B2 · Yang et al. · 2013 [cited by applicant]
US 8465769B2 · Petereit et al. · 2013 [cited by applicant]
US 8466277B2 · Orlando et al. · 2013 [cited by applicant]
US 8575348B2 · Rao et al. · 2013 [cited by applicant]
US 8696696B2 · Solem · 2014 [cited by applicant]
US 8709076B1 · Matheny et al. · 2014 [cited by applicant]
US 8753674B2 · Helson · 2014 [cited by applicant]
US 8828432B2 · Lengerich · 2014 [cited by applicant]
US 8865213B2 · Sheth et al. · 2014 [cited by applicant]
US 8871452B2 · Lee · 2014 [cited by applicant]
US 8906847B2 · Cleemann et al. · 2014 [cited by applicant]
US 8962574B2 · Reilly · 2015 [cited by applicant]
US 8987262B2 · Leaute-Labreze et al. · 2015 [cited by applicant]
US 9011526B2 · Matheny · 2015 [cited by applicant]
US 9016221B2 · Brennan et al. · 2015 [cited by applicant]
US 9044319B2 · Matheny · 2015 [cited by applicant]
US 9060969B2 · Matheny · 2015 [cited by applicant]
US 9078929B2 · Kuebelbeck et al. · 2015 [cited by applicant]
US 9161952B2 · Matheny et al. · 2015 [cited by applicant]
US 9239333B2 · Snider · 2016 [cited by applicant]
US 9255104B2 · Rao et al. · 2016 [cited by applicant]
US 9308084B2 · Matheny · 2016 [cited by applicant]
US 9399067B2 · Mosher et al. · 2016 [cited by applicant]
US 9474719B2 · Mullen et al. · 2016 [cited by applicant]
US 9498481B2 · Rao et al. · 2016 [cited by applicant]
US 9549912B2 · Milner et al. · 2017 [cited by applicant]
US 9554989B2 · Kaplan et al. · 2017 [cited by applicant]
US 9585851B2 · Yun et al. · 2017 [cited by applicant]
US 9585884B2 · Rao et al. · 2017 [cited by applicant]
US 9597302B1 · Yan et al. · 2017 [cited by applicant]
US 9616026B2 · Singh · 2017 [cited by applicant]
US 9682041B2 · Helson · 2017 [cited by applicant]
US 9724297B2 · Thomas et al. · 2017 [cited by applicant]
US 9770514B2 · Ghebre-Sellassie et al. · 2017 [cited by applicant]
US 9889148B2 · Daemmgen et al. · 2018 [cited by applicant]
US 9995756B2 · Saffitz et al. · 2018 [cited by applicant]
US 10117881B2 · Helson · 2018 [cited by applicant]
US 10238602B2 · Helson et al. · 2019 [cited by applicant]
US 10258691B2 · Helson et al. · 2019 [cited by applicant]
US 10349884B2 · Helson et al. · 2019 [cited by applicant]
US 10357458B2 · Helson · 2019 [cited by applicant]
US 10449193B2 · Helson et al. · 2019 [cited by applicant]
US 10450267B2 · Stancl · 2019 [cited by applicant]
US 10512620B1 · Somberg et al. · 2019 [cited by applicant]
US 10537588B2 · Daemmgen et al. · 2020 [cited by applicant]
US 10603316B2 · Xiong et al. · 2020 [cited by applicant]
US 10617639B2 · Helson · 2020 [cited by applicant]
US 10793519B2 · Somberg et al. · 2020 [cited by applicant]
US 10799138B2 · Ivaturi et al. · 2020 [cited by applicant]
US 10888524B2 · Yenkar et al. · 2021 [cited by applicant]
US 10888552B2 · Rothman · 2021 [cited by applicant]
US 11286235B2 · Somberg et al. · 2022 [cited by applicant]
US 11344518B2 · Somberg · 2022 [cited by applicant]
US 11364213B2 · Somberg · 2022 [cited by applicant]
US 11583216B2 · Ivaturi et al. · 2023 [cited by applicant]
US 11610660B1 · Devlin et al. · 2023 [cited by applicant]
US 11696902B2 · Somberg et al. · 2023 [cited by applicant]
US 11957648B2 · Somberg · 2024 [cited by applicant]
US 20070009564A1 · McClain et al. · 2007 [cited by applicant]
US 20070009654A1 · Watanabe et al. · 2007 [cited by applicant]
US 20120003318A1 · Schuler et al. · 2012 [cited by applicant]
US 20140235631A1 · Bunt et al. · 2014 [cited by applicant]
US 20140276404A1 · Orlowski · 2014 [cited by applicant]
US 20150081010A1 · Matheny · 2015 [cited by applicant]
US 20150210712A1 · Blumberg et al. · 2015 [cited by applicant]
US 20160082159A1 · Orlowski · 2016 [cited by applicant]
US 20160128944A1 · Chawrai et al. · 2016 [cited by applicant]
US 20160228379A1 · Kumar et al. · 2016 [cited by applicant]
US 20160271070A1 · Singh et al. · 2016 [cited by applicant]
US 20160271157A1 · Ahmed et al. · 2016 [cited by applicant]
US 20160303133A1 · Dudley et al. · 2016 [cited by applicant]
US 20160317388A1 · Bhargava et al. · 2016 [cited by applicant]
US 20170049705A1 · Mateescu et al. · 2017 [cited by applicant]
US 20170087105A1 · Yan et al. · 2017 [cited by applicant]
US 20170100387A1 · Arora et al. · 2017 [cited by applicant]
US 20170119627A1 · Bhargava et al. · 2017 [cited by applicant]
US 20170157076A1 · Yacoby-Zeevi et al. · 2017 [cited by applicant]
US 20170231885A1 · Cremers et al. · 2017 [cited by applicant]
US 20170258781A1 · Noujaim et al. · 2017 [cited by applicant]
US 20170296493A1 · Thomas et al. · 2017 [cited by applicant]
US 20170348303A1 · Bosse et al. · 2017 [cited by applicant]
US 20180071390A1 · Patel et al. · 2018 [cited by applicant]
US 20190307343A1 · Ivaturi et al. · 2019 [cited by applicant]
US 20190352257A1 · Somberg et al. · 2019 [cited by applicant]
US 20190380605A1 · Ivaturi et al. · 2019 [cited by applicant]
US 20190388371A1 · Somberg · 2019 [cited by applicant]
US 20190389888A1 · McChesney et al. · 2019 [cited by applicant]
US 20200085771A1 · Somberg et al. · 2020 [cited by applicant]
US 20200093759A1 · Somberg et al. · 2020 [cited by applicant]
US 20200226481A1 · Sim et al. · 2020 [cited by applicant]
US 20200253903A1 · Somberg · 2020 [cited by applicant]
US 20200338027A1 · Somberg · 2020 [cited by applicant]
US 20200383941A1 · Brelidze et al. · 2020 [cited by applicant]
US 20210076959A1 · Ivaturi et al. · 2021 [cited by applicant]
US 20210107867A1 · Somberg et al. · 2021 [cited by applicant]
US 20210283049A1 · Somberg · 2021 [cited by applicant]
US 20210346325A1 · Somberg · 2021 [cited by applicant]
US 20220142954A1 · Somberg · 2022 [cited by applicant]
US 20220241225A1 · Somberg · 2022 [cited by applicant]
US 20220339130A1 · Somberg et al. · 2022 [cited by applicant]
US 20230075398A1 · Devlin et al. · 2023 [cited by applicant]
US 20230187049A1 · Devlin et al. · 2023 [cited by applicant]
US 20230225664A1 · Ivaturi et al. · 2023 [cited by applicant]
US 20230225997A1 · Kashfian · 2023 [cited by applicant]
US 20230248674A1 · Kashfian · 2023 [cited by applicant]
US 20230255908A1 · Kashfian · 2023 [cited by applicant]
US 20230255909A1 · Kashfian · 2023 [cited by applicant]
US 20230270940A1 · Devlin et al. · 2023 [cited by applicant]
US 20230285273A1 · Kashfian · 2023 [cited by applicant]
US 20230293426A1 · Kashfian · 2023 [cited by applicant]
US 20230293455A1 · Somberg et al. · 2023 [cited by applicant]
US 20230310745A1 · Kashfian · 2023 [cited by applicant]
US 20230372268A1 · Kashfian · 2023 [cited by applicant]
US 20240156758A1 · Somberg · 2024 [cited by applicant]
US 20240261242A1 · Kashfian · 2024 [cited by applicant]
US 20250140361A1 · Kashfian et al. · 2025 [cited by applicant]
US 20250152529A1 · Somberg et al. · 2025 [cited by applicant]
US 20250152530A1 · Somberg et al. · 2025 [cited by applicant]
US 20250213504A1 · Kashfian et al. · 2025 [cited by applicant]
AU 737668B2 · 2001 [cited by applicant]
AU 765269B2 · 2003 [cited by applicant]
AU 2003233653A1 · 2003 [cited by applicant]
AU 2005299693A1 · 2006 [cited by applicant]
AU 2010231494A1 · 2011 [cited by applicant]
AU 2013203252A1 · 2013 [cited by applicant]
AU 2013381856A1 · 2015 [cited by applicant]
AU 2011289176B2 · 2015 [cited by applicant]
AU 2016266020B2 · 2018 [cited by applicant]
AU 2017357916A1 · 2019 [cited by applicant]
AU 2016313439B2 · 2019 [cited by applicant]
AU 2015269699B2 · 2020 [cited by applicant]
EP 0898964A1 · 1999 [cited by applicant]
EP 1027329B1 · 2003 [cited by applicant]
EP 1467705A2 · 2004 [cited by applicant]
EP 1474105A2 · 2004 [cited by applicant]
EP 1605976A1 · 2005 [cited by applicant]
EP 2429291A1 · 2012 [cited by applicant]
EP 1501467B1 · 2012 [cited by applicant]
EP 2238127B1 · 2012 [cited by applicant]
EP 2238128B1 · 2012 [cited by applicant]
EP 2228065B1 · 2012 [cited by applicant]
EP 2797556A1 · 2014 [cited by applicant]
EP 2861254A2 · 2015 [cited by applicant]
EP 3100728A1 · 2016 [cited by applicant]
EP 2999461A4 · 2017 [cited by applicant]
EP 2714011B1 · 2018 [cited by applicant]
EP 1951210B1 · 2018 [cited by applicant]
WO 9921829A1 · 1999 [cited by applicant]
WO 03020240A2 · 2003 [cited by applicant]
WO 03059318A2 · 2003 [cited by applicant]
WO 2004082716A1 · 2004 [cited by applicant]
WO 2007053393A2 · 2007 [cited by applicant]
WO 2010132711A1 · 2010 [cited by applicant]
WO 2012167212A3 · 2013 [cited by applicant]
WO 2013185764A2 · 2013 [cited by applicant]
WO 2014133539A1 · 2014 [cited by applicant]
WO 2014143108A1 · 2014 [cited by applicant]
WO 2014186843A1 · 2014 [cited by applicant]
Bianconi et al., publication titled “Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter”, (Year: 2000). [cited by examiner]
Dailymed website: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Year: 1999). [cited by examiner]
Co-Pending U.S. Appl. No. 16/103,815, Response to Feb. 6, 2019 Non-Final Office Action, filed May 6, 2019, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Restriction Requirement dated Dec. 13, 2018, 6 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Final Office Action dated Mar. 27, 2020, 12 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Non-final Office Action dated Nov. 12, 2019, 12 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Notice of Allowance and Examiner Initiated Interview Summary dated Jun. 10, 2020, 8 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Response to Mar. 27, 2020 Final Office Action dated May 27, 2020, 11 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Response to Nov. 12, 2019 Non-Final Office Action filed Feb. 12, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Final Office Action dated Sep. 3, 2021, 20 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Feb. 7, 2020, 12 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Jul. 21, 2022, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Notice of Allowance dated Mar. 9, 2023, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Petition Decision dated Mar. 29, 2021, 2 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Feb. 7, 2020 Non-Final Office Action, filed May 5, 2020, 20 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Jul. 21, 2022 Non-Final Office Action including Rule 132 Affidavit, dated Jan. 20, 2023, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Sep. 3, 2021 Final Office Action, dated Feb. 3, 2022, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Final Office Action dated Mar. 29, 2021, 14 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Final Office Action dated Oct. 14, 2022, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Jan. 7, 2022, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Oct. 20, 2020, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Jan. 7, 2022 Non-Final Office Action, dated Jul. 6, 2022, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Mar. 29, 2021 Final Office Action, filed Sep. 29, 2021, 13 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Oct. 14, 2022 Final Office Action dated Apr. 14, 2023, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Oct. 20, 2020 Non-Final Office Action, filed Feb. 22, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Final Office Action dated Feb. 3, 2021, 24 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Non-Final Office Action dated Jul. 9, 2020, 19 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Notice of Abandonment, Aug. 20, 2021, 2 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Response to Jul. 9, 2020 Non-Final Office Action, dated Dec. 9, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Advisory Action dated Dec. 30, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Dec. 28, 2020, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Oct. 26, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action and Examiner Initiated Interview Summary dated Jun. 9, 2021, 14 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action dated Jun. 4, 2020, 18 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 4, 2020 Non-Final Office Action dated Dec. 4, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 9, 2021 Non-Final Office Action dated Oct. 12, 2021, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to May 13, 2020 Restriction Requirement, filed May 26, 2020, 44 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Oct. 26, 2021 Final Office Action, dated Dec. 10, 2021, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Restriction Requirement dated May 13, 2020, 5 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Non-Final Office Action dated Feb. 7, 2022, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Notice of Allowance dated Apr. 4, 2022, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Preliminary Amendment filed Jan. 20, 2021, 3 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Response to Feb. 7, 2022 Non-Final Office Action, dated Mar. 8, 2022, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/306,490, Preliminary Amendment filed Dec. 7, 2022, 38 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Non-Final Office Action dated Mar. 23, 2022, 11 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Jul. 25, 2022, 7 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Nov. 9, 2022, 7 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Petition Under 37 CFR 1.181 and Preliminary Amendment, dated Feb. 22, 2022, 9 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Response to Mar. 23, 2022 Non-Final Office Action, dated Jul. 7, 2022, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/585,190, Preliminary Amendment dated Mar. 4, 2022, 4 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/585,190, Restriction Requirement dated Oct. 19, 2023, 5 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Preliminary Amendment dated Jul. 10, 2022, 4 pages. [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 17/566,840, filed Dec. 31, 2021, Specification, Claims, and Figures. [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 18/107,785, filed Feb. 9, 2023, Specification, Claims, and Figures. [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 18/121,980, filed Mar. 15, 2023, Specification, Claims, and Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 16/376,706, filed Apr. 5, 2019, Specification, Claims, Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 16/549,620, filed Aug. 23, 2019, Specification, Claims, Figures and File History as of Dec. 2020, 77 pages (abandoned). [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 17/003,297, filed Aug. 26, 2020, Specification, Claims, Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 18/156,092, filed Jan. 18, 2023, Specification, Claims, Figures. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/126,561, filed Mar. 27, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/135,467, filed Apr. 17, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/304,196, filed Apr. 20, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/306,660, filed Apr. 25, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/315,790, filed May 11, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/321,220, filed May 22, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/323,337, filed May 24, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/324,703, filed May 26, 2023, Specification and Claims. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/103,815, filed Aug. 14, 2018, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/693,310, filed Nov. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/693,312, filed Nov. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/726,361, filed Dec. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 17/861,226, filed Jul. 10, 2022, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 18/322,111, filed May 23, 2023, Specification, Claims, Figures. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/849,099, filed Apr. 15, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/863,567, filed Apr. 30, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/946,941, filed Jul. 13, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/306,490, filed May 3, 2021, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/585,190, filed Jan. 26, 2022, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/725,189, filed Apr. 20, 2022, Specification and Claims. [cited by applicant]
Amiodarone HCI injection for intravenous use [package insert], Lake Forest, IL: Hospira, Inc.; Initial U.S. Approval: 1995, 4 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Final Office Action dated Jul. 27, 2022, 16 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Non-Final Office Action dated Mar. 14, 2022, 14 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Notice of Allowance dated Oct. 18, 2022, 7 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Preliminary Amendment filed Dec. 8, 2020, 9 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Response to Final Office Action dated Sep. 27, 2022, 12 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Response to Mar. 14, 2022 Non-Final Office Action, dated Jun. 15, 2022, 12 pages. [cited by applicant]
Barbey, J.T. “Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects,” Clinical Pharmacology and Therapeutics vol. 66(1) (1999) 91-99. [cited by applicant]
Bashir, Y. et al., “Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia” The American Journa… [cited by applicant]
Batra, Anjan S., et al., “Junctional ectopic tachycardia: Current strategies for diagnosis and management,” Progress in Pediatric Cardiology, 35 (2013) 49-54. [cited by applicant]
Batul, S.A., “Intravenous sotalol: Reintroducing a forgotten agent to the electrophysiology therapeutic arsenal,” J. Atrial Fibrillation vol. 9(3) (Feb.-Mar. 2017) 1-5. [cited by applicant]
Blair, Andrew D., et al., Sotalol kinetics in renal insufficiency, Clin. Pharmacol. Ther., 457-463 (Apr. 1981) (7 pages). [cited by applicant]
Boriani, G. et al., Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology. 2004; 95, 245-250. [cited by applicant]
Borquez, Alejandro A., et al., “Intravenous Sotalol in the Young, Safe and Effective Treatment With Standardized Protocols,” JACC: Clinical Elecrophysiology, vol. 6, No. 4, Apr. 2020:425-32 (2020). [cited by applicant]
Campbell, T.J., “Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bipass comparison with disopyramide and digoxin in a randomised trial,” BR Heart J. (1985) 54:86-90. [cited by applicant]
Cantillon, D. J. and Amuthan, R. “Atrial Fibrillation”, Cleveland Clinic: Center for Continuing Education, Disease Management: https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/atrial-fibrill… [cited by applicant]
Choc Children's, “Junctional Ectopic Tachycardia (JET) Care Guideline for Cardiovascular Intensive Care Unit (CVICU),” Sep. 18, 2019. [cited by applicant]
Cilliers, Antionette M., et al., “Junctional ectopic tachycardia in six paediatric patients,” Heart; 78:413-415 (1997). [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Final Office Action dated Aug. 13, 2019, 13 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Non-Final Office Action dated Feb. 6, 2019, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Notice of Allowance dated Oct. 30, 2019, 12 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Response to Aug. 13, 2019 Final Office Action, filed Oct. 17, 2019, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Response to Dec. 13, 2018 Restriction Requirement, filed Dec. 31, 2018, 3 pages. [cited by applicant]
Cordarone® (amiodarone HCI) Tablets [package insert], Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2004, 29 pages. [cited by applicant]
Dahmane, E., “Clinical Pharmacology-Driven Research to Optimize Bedside Therapeutics of Sotalol Therapy,” Clin Transl Sci (2019) 12:648-656. [cited by applicant]
Dumas, M. et al., “Variations of sotalol kinetics in renal insufficiency”, International Journal of Clinical Pharmacology, Therapy, and Toxicology, Oct. 1, 1989, 27(10), Abstract only. [cited by applicant]
El-Assaad, I, “Lone Pediatric Atrial Fibrillation in the United States: Analysis of Over 1500 Cases,” Pediatr. Cardiol. 38:1004-1009, Springer Publishing, United States (2017). [cited by applicant]
FDA Highlights of Prescribing Information sotalol hydrochloride injection (2009), https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022306s000lbl.pdf. [cited by applicant]
FDA Highlights of Prescribing Information Sotylize (sotalol hydrochloride (2014), https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205108s000lbl.pdf. [cited by applicant]
FDA “Highlights of Prescribing Information” for sotalol hydrochloride injection, Revised Mar. 2020, 16 pages, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022306s005lblrpl.pdf. [cited by applicant]
Flecainide Acetate Tablets, USP [package insert], Jacksonville, FL: Ranbaxy Pharmaceuticals Inc.; 2003, 17 pages. [cited by applicant]
Galloway, C.D., “Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram,” JAMA Cardiol.: E1-E9, Amer. Med. Assoc., United States (Apr. 3, 2019). [cited by applicant]
Gomes, J.A., “Oral d,l Sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study,” J. Am. Coll. Cardio. 34(2):334… [cited by applicant]
Hannun, A.Y., “Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network,” Nature Medicine 25:65-69, Nature Publishing (Jan. 2019). [cited by applicant]
Ho, D.S.W, et al., “Rapid intravenous infusion of d-l sotalol: time to onset of effects on ventricular refractoriness, and safety,” European Heart J. 16:81-86, European Soc. of Cardiology, UK (1995). [cited by applicant]
Hoffman et al. “Renal Insufficiency and Medication in Nursing Homes” Medicine Deutsches Arzteblatt International 2016; 113: 92-98. [cited by applicant]
Ibutilide Fumarate Injection [package insert], Morgantown, WV: Mylan Institutional LLC; 2020, 14 pages. [cited by applicant]
Kerin, Nicholas A., “Intravenous Sotalol: an under used treatment strategy,” Cardiology (2018) 140:143-145. [cited by applicant]
Laer, S., et al., “Development of a safe and effective pediatric dosing regimen for sotalol based population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia . . . ” Pediatric Cardiolo… [cited by applicant]
Le Coz, F. et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995; 57:533. [cited by applicant]
Learn the Heart, “Antiarrhythmic Drug Review,” https://www.healio.com/cardiology/learn-the-heart/cardiology-review/topic-reviews/antiarrhythmic-drugs (Year: 2022). [cited by applicant]
Li, X, “Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children,” Amer. J. of Cardiology (2017) 119:1366-1370. [cited by applicant]
Li, X., “Pediatric dosing of intravenous sotalol based on body surface area in patients with arrhythmia,” Pediatr Cardiol (2017) 38:1450-1455. [cited by applicant]
Lynch, J.J., et al., “Prevention of ventricular fibrillation by dextrorotatory sotalol in conscious canine model of sudden coronary death,” Amer. Heart J. vol. 109(5) Part 1, (1985) 949-958. [cited by applicant]
Maragnes, P., et al., “Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia,” Int'l J. of Cardiology, 35 (1995) 165-167. [cited by applicant]
Marill, K.A., “Meta-analysis of the risk of torsades de pointes in patients treated with intravenous racemic sotalol,” Academic Emergency Medicine 8(2):117-124, Wiley, United States (2001). [cited by applicant]
Multaq (dronedarone) tablets, for oral use [package insert], Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2020, 24 pages. [cited by applicant]
Neumar, R.W., et al., “Part 8: Adult advanced cardiovascular life support,” Circulation (2010) 122, suppl. 3, S729-S767. [cited by applicant]
Patel, A., “Is Sotalol more effective than standard beta-blockers for prophylaxis of atrial fibrillation during cardiac surgery?” Interactive CardioVascular and Thoracic Surgery 4 (2005) 147-50. [cited by applicant]
Peters, F.P.J., “Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide,” Netherlands J. of Medicine 53:93-96, Elsevier Science B.B., Netherlands (1998). [cited by applicant]
Peters, N.S., “Post-cardioversion atrial fibrillation: the synthesis of modern concepts?” european Heart J. (2000) 21, 1119-1121. [cited by applicant]
Procainamide Dosage. Drugs.com. Last updated Sep. 13, 2021. 3 pages. [cited by applicant]
Procainamide Hydrochloride Injection, USP [package insert], Lake Forest, IL: Hospira, Inc.; 2021, 12 pages. [cited by applicant]
Radford, D.J., “Atrial Fibrillation in Children,” Pediatrics 59(2):250-256, Amer. Acad. of Pediatrics, US (1977). [cited by applicant]
Rasmussen, H.S. et al., Dofetilide, A Novel Class III Antiarrhythmic Agent, J Cardiovasc Pharmacol. 1992;20 Suppl 2:S96-105. [cited by applicant]
Rosseau, M. F., Cardiac and Hemodynamic Effects of Intravenous Dofetilide in Patients With Heart Failure, Am J Cardiol 2001;87:1250-1254. [cited by applicant]
Rythmol (propafenone hydrochloride tablets), for oral use [package insert], Research Triangle Park, NC: GlaxoSmithKline; 2018, 24 pages. [cited by applicant]
Sanjuan, R., “Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery,” Ann Thorac Surg (2004) 77:838-43. [cited by applicant]
Saul, J.P., “Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia,” Clinical Pharma & Therapeutics 69(3): 145-157 (2001). [cited by applicant]
Sedgwick, M. et al., Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug, Br. J. Clin. Pharmac. (1991), 31, 515-519. [cited by applicant]
Snider, M., et al., “Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review,” Clinical Therapeutics vol. 31(36) (2009) 1209-1218. [cited by applicant]
Somberg, et al., “Sotalol versus Amiodarone in Treatment of Atrial Fibrillation,” J. Atrial Fibrillation, Feb.-Mar. 2016, vol. Issue 5. [cited by applicant]
Somberg, J.C., “Gender differences in cardiac repolarization following intravenous sotalol administration,” J. Cardiovascular Pharmacology and Therapeutics (2012) 17(1) 86-92. [cited by applicant]
Somberg, J.C., “QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol,” Cardiology (2010) 116(3):219-25. [cited by applicant]
Somberg, J.C., et al., “Developing a safe intravenous sotalol dosing regimen,” Amer. J. of Therapeutics 17(2010) 365-372. [cited by applicant]
Somberg, John et al. Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. Cardiol Res. 2020; 11(5):294-304. [cited by applicant]
Sundquist, H.K. et al., “Serum levels and half-life of sotalol in chronic renal failure”, Annals of Clinical Research, Dec. 1, 1975, 7(6), Abstract Only. [cited by applicant]
Thomas, S.P., “Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: A randomized, digoxin-controlled trial,” Am. Heart J., 147(1) (6 pages) (2004). [cited by applicant]
Tikosyn® (dofetilide) Capsules [package insert], NY, NY: Pfizer Inc.; 2014, 30 pages. [cited by applicant]
Tse, H.F., “Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion,” european Heart J. (2000) 21, 1167-1176. [cited by applicant]
U.S. Appl. No. 16/376,706 (U.S. Pat. No. 10,799,138), file history Dec. 2020, 151 pages. [cited by applicant]
Valdes, S.O., “Early experience with intravenous sotalol in children with and without congenital heart disease,” Heart Rhythm 15(12): 1862-1869, Elsevier Inc., (Jul. 9, 2018). [cited by applicant]
Yarlagadda, B, et al., “Safety and efficacy of inpatient initiation of dofetilide versus sotalol for atrial fibrillation,” J. Atrial Fibrillation vol. 101(4) (2017) 1-5. [cited by applicant]
(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 19/009,774), filed Jan. 3, 2025, Specification, Drawings, and Claims. [cited by applicant]
(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 19/080,585, filed Mar. 14, 2025, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/631,538, filed Apr. 10, 2024, Specification and Claims. [cited by applicant]
(Somberg, John et al.) Co-Pending U.S. Appl. No. 19/019,556, filed Jan. 14, 2025, Specification and Claims. [cited by applicant]
(Somberg, John et al.) Co-Pending U.S. Appl. No. 19/022,878, filed Jan. 15, 2025, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 18/417,748, filed Jan. 19, 2024, Specification and Claims. [cited by applicant]
U.S. Appl. No. 18/156,092, Response to Notice to File Missing Parts and Preliminary Amendment, dated Apr. 4, 2023, 6 pages. [cited by applicant]
Brugada, J. et al., 2019 ESC Guidelines for the management of patients with supraventricular tachycardia, European Heart Journal (2020) 41, 655-720, 66 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Final Office Action dated Feb. 22, 2024, 23 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Interview Summary dated Feb. 22, 2024, 1 page. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Aug. 19, 2024, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Nov. 1, 2023, 18 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Notice of Allowance dated Apr. 15, 2025, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Aug. 19, 2024 Non-Final Office Action, dated Dec. 19, 2024, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Feb. 22, 2024 Final Office Action, dated May 14, 2024, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Nov. 1, 2023 Non-Final Office Action, dated Feb. 1, 2024, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Rule 132 Affidavit dated Feb. 1, 2024, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/306,490, Final Office Action dated Mar. 11, 2025, 13 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/306,490, Non-Final Office Action dated Jun. 7, 2024, 50 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/306,490, Response to Jun. 7, 2024 Non-Final Office Action, dated Dec. 6, 2024, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/725,189, Non-Final Office Action dated Jun. 18, 2024, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/725,189, Notice of Allowance dated Apr. 30, 2025, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/725,189, Response to Jun. 18, 2024 Non-Final Office Action, dated Dec. 18, 2024, 5 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Final Office Action dated Mar. 21, 2025, 24 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Interview Summary dated Jan. 7, 2025, 2 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Non-Final Office Action dated Jul. 16, 2024, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Response to Jul. 16, 2024 Non-Final Office Action, dated Dec. 16, 2024, 9 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/107,785, Non-Final Office Action dated May 8, 2025, 9 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/107,785, Preliminary Amendment dated Feb. 15, 2024, 10 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/121,980, Preliminary Amendment dated Jul. 18, 2023, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/322,111, Preliminary amendment dated Jan. 31, 2024, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/417,748, Preliminary Amendment dated Apr. 22, 2024, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 19/019,556, Preliminary Amendment dated Jan. 14, 2025, 4 pages. [cited by applicant]
Dwivedi, S.K. et al. “Efficacy of Dual Strategy of Sotalol and Electrical Cardioversion With Balloon Mitral Valvotomy in Persistent Rheumatic Atrial Fibrillation With Mitral Stenosis,” Heart, 2012, 98 (Suppl 2): E1-E319… [cited by applicant]
Falk, Rodney H. et al., Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter, JACC vol. 29, No. 2, 385-90 (Feb. 1997). [cited by applicant]
Frost, L. et al., Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery, International Journal of Cardiology… [cited by applicant]
Kennedy, D. et al. “Efficacy and Safety of Single Day Loading of Intravenous Sotalol Prior to Direct Current Cardioversion for the Termination of Cardiac Atrial Arrhythmias: An Observational Study,” Heart Rhythm, vol. 1… [cited by applicant]
Kerin, N. Z. and Jacob, S., The Efficacy of Sotalol in Preventing Postoperative Atrial Fibrillation: A Meta-Analysis, The American Journal of Medicine, vol. 124, No. 9, Sep. 2011, 9 pages. [cited by applicant]
Kijtawornrat, A. et al., Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts, The Journal of Toxicological Sciences, 2012, vol. 37, No. 3, 455-462. [cited by applicant]
Cited By (1)
US 12,740,947